U.S. markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.94 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.92 (-0.21%)
     
  • Crude Oil

    83.98
    +1.48 (+1.79%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • Silver

    24.39
    +0.22 (+0.91%)
     
  • EUR/USD

    1.1650
    +0.0019 (+0.16%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • GBP/USD

    1.3760
    -0.0036 (-0.26%)
     
  • USD/JPY

    113.4800
    -0.5080 (-0.45%)
     
  • BTC-USD

    60,944.09
    -1,679.71 (-2.68%)
     
  • CMC Crypto 200

    1,453.34
    -49.69 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.27 (+0.34%)
     

Eli Lilly to supply the U.S. government with doses of COVID-19 treatment etesevimab for $330 million

·1 min read
Eli Lilly to supply the U.S. government with doses of COVID-19 treatment etesevimab for $330 million
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Eli Lilly & Co. announced Wednesday to sell 388,000 doses of etesevimab, which has been authorized for emergency use as a COVID-19 treatment for $330 million. As part of the deal, about 200,000 doses of etesevimab, which complements doses of bamlanivimab previously purchased by the U.S. government, are expected to ship in the third quarter of 2021, with the remaining doses to be shipped in the fourth quarter. "The recent increase in COVID-19 cases has caused a substantial rise in the utilization